软骨发育不全患儿的临床特征及<italic>FGFR3</italic>基因变异分析

doi:10.7499/j.issn.1008-8830.2111039

摘要
图/表
参考文献(29)
相关文章 (15)
点击分布统计
下载分布统计

全文: PDF (631 KB) [HTML]
输出: BibTeX | EndNote (RIS) 背景资料

摘要目的分析17例软骨发育不全（achondroplasia，ACH）患儿的临床特征及成纤维细胞生长因子受体3（fibroblast growth factor receptor 3，FGFR3）基因变异情况。方法回顾性分析2009年1月至2021年10月确诊的17例ACH患儿临床资料及FGFR3基因检测结果。结果 ACH最常见的临床表现是不匀称型身材矮小（100%，17/17）、大头畸形（100%，17/17）、三叉戟手畸形（82%，14/17）、膝内翻（88%，15/17）。最普遍的影像学是根茎状长骨缩短（100%，17/17）和腰椎椎间距变窄（88%，15/17）。主要并发症有骨骼异常（100%，17/17）、中耳功能障碍（82%，14/17）、运动及语言发育迟缓（88%，15/17）、慢性疼痛（59%，10/17）、睡眠呼吸暂停（53%，9/17）、肥胖（41%，7/17）、枕骨大孔缩小（35%，6/17）、脑积水（24%，4/17）。17例（100%）均存在FGFR3基因变异，13例为FGFR3基因c.1138G>A的热点突变；2例FGFR3基因c.1138G>C变异；2例为未报道的变异，其中1例FGFR3基因c.1252C>T变异，1例FGFR3基因c.445+2_445+5delTAGG变异。结论该研究检出FGFR3基因未报道变异位点，扩展了ACH基因变异谱。ACH是一种进行性发展的疾病，其相关并发症由多学科团队协作进行终身管理。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	张惠琴
	陶东英
	张静静
	牛焕红
	罗建峰
	成胜权

关键词 ：软骨发育不全, 成纤维细胞生长因子受体3基因, 基因变异, 儿童

Abstract：Objective To study the clinical features and fibroblast growth factor receptor 3 (FGFR3) gene mutations of children with achondroplasia (ACH) through an analysis of 17 cases. Methods A retrospective analysis was performed on the clinical data and FGFR3 gene detection results of 17 children with ACH who were diagnosed from January 2009 to October 2021. Results Of the 17 children with ACH, common clinical manifestations included disproportionate short stature (100%, 17/17), macrocephaly (100%, 17/17), trident hand (82%, 14/17), and genu varum (88%, 15/17). The common imaging findings were rhizomelic shortening of the long bones (100%, 17/17) and narrowing of the lumbar intervertebral space (88%, 15/17). Major complications included skeletal dysplasia (100%, 17/17), middle ear dysfunction (82%, 14/17), motor/language developmental delay (88%, 15/17), chronic pain (59%, 10/17), sleep apnea (53%, 9/17), obesity (41%, 7/17), foramen magnum stenosis (35%, 6/17), and hydrocephalus (24%, 4/17). All 17 children (100%) had FGFR3 mutations, among whom 13 had c.1138G>A hotspot mutations of the FGFR3 gene, 2 had c.1138G>C mutations of the FGFR3 gene, and 2 had unreported mutations, with c.1252C>T mutations of the FGFR3 gene in one child and c.445+2_445+5delTAGG mutations of the FGFR3 gene in the other child. Conclusions This study identifies the unreported mutation sites of the FGFR3 gene, which extends the gene mutation spectrum of ACH. ACH is a progressive disease requiring lifelong management through multidisciplinary collaboration.

Key words： Achondroplasia Fibroblast growth factor receptor 3 gene Gene mutation Child

收稿日期: 2021-11-07

通讯作者: 成胜权，男，主任医师。Email：chengsq999999@163.com。 E-mail: chengsq999999@163.com

作者简介: 张惠琴，女，硕士，副主任医；

引用本文:

张惠琴,陶东英,张静静等. 软骨发育不全患儿的临床特征及FGFR3基因变异分析[J]. 中国当代儿科杂志, 2022, 24(4): 405-410.

ZHANG Hui-Qin,TAO Dong-Ying,ZHANG Jing-Jing et al. Clinical features and FGFR3 mutations of children with achondroplasia[J]. CJCP, 2022, 24(4): 405-410.

链接本文:

http://www.zgddek.com/CN/10.7499/j.issn.1008-8830.2111039 或 http://www.zgddek.com/CN/Y2022/V24/I4/405

	中国医师协会医学遗传医师分会, 中华医学会儿科学分会内分泌遗传代谢学组, 中华医学会儿科学分会罕见病学组, 等. 软骨发育不全诊断及治疗专家共识[J]. 中华儿科杂志, 2021, 59(7): 545-550. PMID: 34405635. DOI: 10.3760/cma.j.cn112140-20201229-01142.
	Unger S, Bonafé L, Gouze E. Current care and investigational therapies in achondroplasia[J]. Curr Osteoporos Rep, 2017, 15(2): 53-60. PMID: 28224446. PMCID: PMC5435778. DOI: 10.1007/s11914-017-0347-2.
	Pauli RM. Achondroplasia: a comprehensive clinical review[J]. Orphanet J Rare Dis, 2019, 14(1): 1. PMID: 30606190. PMCID: PMC6318916. DOI: 10.1186/s13023-018-0972-6.
	Le Merrer M, Rousseau F, Legeai-Mallet L, et al. A gene for achondroplasia-hypochondroplasia maps to chromosome 4p[J]. Nat Genet, 1994, 6(3): 318-321. PMID: 8012398. DOI: 10.1038/ng0394-318.
	代伟倩, 顾学范, 余永国. 中国210例软骨发育不全患儿临床遗传特征分析及生长发育曲线探索[J]. 中华儿科杂志, 2020, 58(6): 461-467. PMID: 32521957. DOI: 10.3760/cma.j.cn112140-20200217-00096.
	Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology[J]. Genet Med, 2015, 17(5): 405-424. PMID: 25741868. PMCID: PMC4544753. DOI: 10.1038/gim.2015.30.
	H?gler W, Ward LM. New developments in the management of achondroplasia[J]. Wien Med Wochenschr, 2020, 170(5-6): 104-111. PMID: 32144686. PMCID: PMC7098936. DOI: 10.1007/s10354-020-00741-6.
	Wrobel W, Pach E, Ben-Skowronek I. Advantages and disadvantages of different treatment methods in achondroplasia: a review[J]. Int J Mol Sci, 2021, 22(11): 5573. PMID: 34070375. PMCID: PMC8197470. DOI: 10.3390/ijms22115573.
	Cormier-Daire V, AlSayed M, Ben-Omran T, et al. The first European consensus on principles of management for achondroplasia[J]. Orphanet J Rare Dis, 2021, 16(1): 333. PMID: 34332609. PMCID: PMC8325831. DOI: 10.1186/s13023-021-01971-6.
	Ornitz DM, Legeai-Mallet L. Achondroplasia: development, pathogenesis, and therapy[J]. Dev Dyn, 2017, 246(4): 291-309. PMID: 27987249. PMCID: PMC5354942. DOI: 10.1002/dvdy.24479.
	Coi A, Santoro M, Garne E, et al. Epidemiology of achondroplasia: a population-based study in Europe[J]. Am J Med Genet A, 2019, 179(9): 1791-1798. PMID: 31294928. DOI: 10.1002/ajmg.a.61289.
	Tenconi R, Khirani S, Amaddeo A, et al. Sleep-disordered breathing and its management in children with achondroplasia[J]. Am J Med Genet A, 2017, 173(4): 868-878. PMID: 28239978. DOI: 10.1002/ajmg.a.38130.
	Kubota T, Adachi M, Kitaoka T, et al. Clinical practice guidelines for achondroplasia[J]. Clin Pediatr Endocrinol, 2020, 29(1): 25-42. PMID: 32029970. PMCID: PMC6958518. DOI: 10.1297/cpe.29.25.
	Okenfuss E, Moghaddam B, Avins AL. Natural history of achondroplasia: a retrospective review of longitudinal clinical data[J]. Am J Med Genet A, 2020, 182(11): 2540-2551. PMID: 32864841. DOI: 10.1002/ajmg.a.61825.
	Hoover-Fong J, Cheung MS, Fano V, et al. Lifetime impact of achondroplasia: current evidence and perspectives on the natural history[J]. Bone, 2021, 146(5): 115872. PMID: 33545406. DOI: 10.1016/j.bone.2021.115872.
	Manikkam SA, Chetcuti K, Howell KB, et al. Temporal lobe malformations in achondroplasia: expanding the brain imaging phenotype associated with FGFR3-related skeletal dysplasias[J]. AJNR Am J Neuroradiol, 2018, 39(2): 380-384. PMID: 29170271. PMCID: PMC7410599. DOI: 10.3174/ajnr.A5468.
	Ireland PJ, Pacey V, Zankl A, et al. Optimal management of complications associated with achondroplasia[J]. Appl Clin Genet, 2014, 7: 117-125. PMID: 25053890. PMCID: PMC4104450. DOI: 10.2147/TACG.S51485.
	Bodensteiner JB. Neurological manifestations of achondroplasia[J]. Curr Neurol Neurosci Rep, 2019, 19(12): 105. PMID: 31782047. DOI: 10.1007/s11910-019-1008-x.
	King JAJ, Vachhrajani S, Drake JM, et al. Neurosurgical implications of achondroplasia[J]. J Neurosurg Pediatr, 2009, 4(4): 297-306. PMID: 19795959. DOI: 10.3171/2009.3.PEDS08344.
	Ireland PJ, Donaghey S, McGill J, et al. Development in children with achondroplasia: a prospective clinical cohort study[J]. Dev Med Child Neurol, 2012, 54(6): 532-537. PMID: 22409389. DOI: 10.1111/j.1469-8749.2012.04234.x.
	Ceroni JRM, Soares DCDQ, Testai LDC, et al. Natural history of 39 patients with achondroplasia[J]. Clinics (Sao Paulo), 2018, 73: e324. PMID: 29972438. PMCID: PMC6005962. DOI: 10.6061/clinics/2018/e324.
	Tunkel D, Alade Y, Kerbavaz R, et al. Hearing loss in skeletal dysplasia patients[J]. Am J Med Genet A, 2012, 158A(7): 1551-1555. PMID: 22628261. DOI: 10.1002/ajmg.a.35373.
	Hoover-Fong J, Scott CI, Jones MC, et al. Health supervision for people with achondroplasia[J]. Pediatrics, 2020, 145(6): e20201010. PMID: 32457214. DOI: 10.1542/peds.2020-1010.
	Fredwall SO, Steen U, de Vries O, et al. High prevalence of symptomatic spinal stenosis in Norwegian adults with achondroplasia: a population-based study[J]. Orphanet J Rare Dis, 2020, 15(1): 123. PMID: 32450891. PMCID: PMC7249360. DOI: 10.1186/s13023-020-01397-6.
	Dhiman N, Albaghdadi A, Zogg CK, et al. Factors associated with health-related quality of life (HRQOL) in adults with short stature skeletal dysplasias[J]. Qual Life Res, 2017, 26(5): 1337-1348. PMID: 27866314. DOI: 10.1007/s11136-016-1455-7.
	Hoover-Fong JE, Schulze KJ, McGready J, et al. Age-appropriate body mass index in children with achondroplasia: interpretation in relation to indexes of height[J]. Am J Clin Nutr, 2008, 88(2): 364-371. PMID: 18689372. DOI: 10.1093/ajcn/88.2.364.
	Saint-Laurent C, Garcia S, Sarrazy V, et al. Early postnatal soluble FGFR3 therapy prevents the atypical development of obesity in achondroplasia[J]. PLoS One, 2018, 13(4): e0195876. PMID: 29652901. PMCID: PMC5898762. DOI: 10.1371/journal.pone.0195876.
	Hoover-Fong J, McGready J, Schulze K, et al. A height-for-age growth reference for children with achondroplasia: expanded applications and comparison with original reference data[J]. Am J Med Genet A, 2017, 173(5): 1226-1230. PMID: 28374958. DOI: 10.1002/ajmg.a.38150.
	Miccoli M, Bertelloni S, Massart F. Height outcome of recombinant human growth hormone treatment in achondroplasia children: a meta-analysis[J]. Horm Res Paediatr, 2016, 86(1): 27-34. PMID: 27355624. DOI: 10.1159/000446958.